## FACULTY

**Laura Amato**, Department of Epidemiology for regional Lazio Health Service (Italy) **Mireille Broeders**, Department for Health Evidence.

Radboud University Medical Centre – Nijmegen (Netherlands)

**Carla Cogo**, Oncological Institute of Veneto (IRCCS) Padova (Italy)

Rosanna D'Antona, Europa Donna - Italy Fabrizio Faggiano, University of Eastern Piedmont Novara, Italian Association of Epidemiology (AIE) (Italy)

**Alfonso Frigerio**, Unit of Epidemiology – CPO Piedmont –Turin (Italy)

**Livia Giordano**, Unit of Epidemiology – CPO Piedmont – Turin (Italy)

Paolo Giorgi Rossi, Organisational Unit of

Epidemiology and Risk Communication – Reggio Emilia (Italy)

**Roberto Grilli**, ARS Emilia Romagna region (Italy) **Solveig Hofvind**, Cancer Registry of Norway (Norway)

Karsten Juhl Jørgensen, Nordic Cochrane Centre – Copenaghen (DK)

Manuela Lerda, Italian Society of General Medicine (Italy)

**Silvia Minozzi**, Department of Epidemiology for regional Lazio Health Service (Italy)

Paola Mosconi, Institute for Pharmacological Research "Mario Negri" / Partecipasalute, (Italy)

Sue Moss, Queen Mary University of London Wolfson Institute (UK)

**Carlo Naldoni**, Department of Public Health Emilia Romagna region (Italy)

**Nick Ormiston-Smith**, Cancer Research UK Member of the Secretariat for the Independent UK Panel on Breast Cancer Screening (UK)

**Eugenio Paci**, Clinical and Descriptive Epidemiology Unit, ISPO -Cancer Prevention and Research Institute, Florence (Italy)

Pietro Panizza, National Institute of Cancer Institute - Milan (Italy)

Antonio Ponti, Unit of Epidemiology – CPO Piedmont –Turin (Italy) Amanda Ramirez, King's Health Partners College London (UK) Carlo Saitto, Local Health Unit Roma E (Italy) Anna Sapino, Department of Molecular Biotechnology and Health Sciences

University of Turin (Italy) Nereo Segnan, Unit of Epidemiology – CPO Piedmont –Turin (Italy)

Robert Smith, American Cancer Society - USA

**Corrado Tinterri**, Clinical Institute Humanitas – Rozzano (Italy) **Marco Zappa**, Clinical and Descriptive Epidemiology Unit, ISPO - Cancer Prevention and Research Institute, Florence (Italy)

## Registration

It is due no entry fee. Participation is limited to the first 100 people who send the registration form duly completed to the Organizing Secretariat no later than January 20, 2014.

The registration form is available on the websites:

www.osservatorionazionalescreening.it www.gisma.it

# To get to the venue

### by car

from Ancona and from Milan, continue to Highway Exit "Fiera"

by train

take bus number 35 or 38 walk 20 minutes

# **Organizing Secretary**



Palazzo Capponi - Via Giusti, 52 50121 Firenze Tel 055 4630555 - Fax 055 476824 congressi@wwes.it susanna.casprini@wwwes.it simona.lumachelli@wwwes.it



The Italian Group for Mammography Screening (GISMa) and the National Screening Monitoring Centre (ONS) in cooperation with the Italian Cochrane Centre, the Italian Association of Epidemiology, Partecipasalute, SIRM, EUROPA DONNA and SIMG organise the workshop:

# European estimates of the mammography screening balance sheet of benefits and harms: challenges for communication and research

# Bologna, 30 January 2014

# Regione Emilia e Romagna Aula Magna - Viale Aldo Moro, 30

In 2012, the publication by the Euroscreen Working Group of the balance sheet of benefits and harms of service screening programmes based on the review of the outcomes of European observational studies and the report of the UK Independent Panel on the National Health Service screening program renewed the interest for the mammography controversy.

The conclusion of the UK Independent Panel was service screening should continue but communication of benefit and harms of screening is warranted. In this workshop we would like to review the evidence on breast cancer screening outcomes, discuss results of the balance sheet of benefits and harms and methodological problems in the evaluation of screening outcomes. The aim is to establish the state of knowledge and how to move towards a better communication of the facts to women and stakeholders and the implications for future challenges in Europe.

M. Zappa, L. Giordano 10.30 The screening mammography controversy Chairs: L. Amato, C. Naldoni A comparison of the mammography R. Smith 10.30-10.55 screening reviews and the Guideline debate in US 10.55-11.20 The state of the controversy and the *N. Ormiston-Smith* UK Panel Independent Review A perspective on screening K. Jørgensen 11.20-11.45 mammography programs impact in Europe Issues in mortality trends evaluation S. Moss 11.45-12.05 E. Paci The Euroscreen review of 12.05-12.30 observational studies 12.30-13.00 F. Faggiano, S. Minozzi Discussion 13.00 Lunch

C. Lusenti

## **AFTERNOON**

	nunication of the outcomes: riences from Europe	
Chairs: R. D'Antona, C. Cogo		
14.00-14.30	Offering informed choice about breast cancer screening: The English Experience	A. Ramirez
14.30-14.40	Breast cancer screening experiences on communication from: The Netherland	M. Broeders
14.40-14.50	Norway	S. Hofvind
14.50-15.00	Italy	L. Giordano
15.00-15-20	Discussion	P. Mosconi. M Lerda
	diagnosis, overtreatment and false ive results	
	onti, P. Panizza	
15.20-15.40	Overdiagnosis and overtreatment: definitions and problems for health services	C. Saitto
15.40-16.00	Overdiagnosis and overtreatment: how to face them?	N. Segnan
16.00-16.15	A comparison of the overdiagnosis estimates in prostate and breast screening	М. Ζарра
16.15-16.35	Estimates of lifetime risk of false positive results	S. Hofvind
16.35-17.00	Discussion	E. Paci, A. Frigerio, C. Tinterri
	e challenges for breast cancer research	
Chairs: S. M		M. Due e de si
17.00-17.20	Towards Horizon 2020: tailored screening as a research challenge	M. Broeders
17.20-17.45	Discussion	A. Sapino, P. Giorgi Rossi
17.45 Conclusion		
	The GISMA-ONS statement and future plans	L. Giordano, E. Paci

18.00 End of the Workshop

#### **30 JANUARY 2014** WORKSHOP

Apertura dei lavori Introduction

MORNING

10.00

10.15